Form 4: Alto Neuroscience Director Acquires Stock Options in Lieu of Retainer Fees

Husseini Manji, a director at Alto Neuroscience, acquired stock options for 14,195 shares in lieu of $45,000 in retainer fees.

Summary

• Husseini Manji, a director of Alto Neuroscience, Inc., filed a Form 4 on January 6, 2025, reporting a transaction that occurred on January 2, 2025.
• Manji acquired stock options for 14,195 shares of Alto Neuroscience common stock.
• The exercise price of the options is $4.38 per share.
• The options were granted in lieu of $45,000 in retainer fees, as part of the Issuer's Non-Employee Director Compensation Policy.
• The options vest in four equal installments of 3,548 or 3,549 shares on March 31, 2025, June 30, 2025, September 30, 2025, and December 31, 2025, contingent upon continuous service.
• The options expire on January 1, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which is a common practice. It doesn't inherently indicate positive or negative sentiment.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Directors often receive stock options as part of their compensation packages.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash and equity.
• Granting stock options in lieu of cash retainer fees is a common practice to align director interests with shareholder value.
• The vesting schedule is fairly standard, promoting long-term commitment from the director.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's long-term success.

Key Dates